Search Results 321-330 of 16555 for Phenothiazines

1. Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as ...

2. Focus areas - Psychiatric Genomics and Pharmacogenomics Program - Mayo Clinic Research

   The Psychiatric Genomics and Pharmacogenomics Program at Mayo Clinic studies links between genetics, bipolar disorder, addiction and alcohol use disorder to ...

3. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

   About this study. This is an open-label extension study to Study 200622.In this study subjects from Study 200622 will be continued on 4-weekly dosing with ...

4. A study of how current treatments impact the course of relapsed myeloma and the effect of the treatments on the quality-of-life measurements. - Mayo Clinic

   The secondary goal is to asses clinical endopoints associated with standard of care therapies for TCR MM, in a real-world setting during 12 months of ...

5. Nicotine Dependence Center - Doctors - Mayo Clinic

   Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota.

6. A Study of Lenalidomide Combined with a Standard Chemotherapy for Treating Patients with Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma - Mayo Clinic

   Lenalidomide may stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new blood vessels necessary for cancer growth. Giving ...

7. Safinamide (oral route) - Side effects & dosage - Mayo Clinic

   Safinamide is used in combination with levodopa and carbidopa to treat adults with Parkinson's disease who are having "off" episodes. This medicine is a MAO-B ...

8. Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

   Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual ...

9. Efficacy, Safety, And Tolerability Study Of Lunsekimig Compared With Placebo In Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized By An Eosinophilic Phenotype PERSEPHONE - Mayo Clinic

   Efficacy, Safety, And Tolerability Study Of Lunsekimig Compared With Placebo In Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary ...

10. A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome - Mayo Clinic

    This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the efficacy, safety, and PK of ZX008 when used as adjunctive therapy ...